Skip to main content
TipRanks
Go Ultimate75% OFF

Insmed (INSM) Revenue by Segment

1,375 Followers

Revenue by Segment

Breaks revenue into business lines—primarily product sales (e.g., ARIKAYCE), licensing, and milestone or collaboration income—to show whether earnings are driven by repeatable commercial performance or one‑time events. For Insmed, a high share of product revenue points to commercial traction and more predictable cash flow, while reliance on milestone/license payments raises volatility. Tracking the mix over time helps assess durability of growth, concentration risk, and the company’s path to sustainable profitability.

$0.00$100.00M$200.00M$300.00M$400.00M$500.00MSep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

BRINSUPRI has become the company’s clear growth engine, delivering a historic launch that materially reweights revenue and allowed management to raise FY guidance and peak sales assumptions; improved gross‑to‑net and rapid prescriber/patient uptake strengthen near‑term margins. ARIKAYCE remains a steady, modest cash generator absent label expansion. Key risks for investors: sustaining ~7,000 new starts/quarter, rising GTN over time, higher R&D/SG&A and a $50M AstraZeneca milestone in H2—offset by a ~$1.2B cash runway and a path to 2027 cash‑flow positivity.

INSM Revenue by Segment

DateARIKAYCEBRINSUPRI
Sep 30, 2026$124.38M$400.05M
Jun 30, 2026$116.32M$309.17M
Mar 31, 2026$98.10M$207.90M
Dec 31, 2025$119.20M$144.60M
Sep 30, 2025$114.30M$28.10M